|
Ayman Sahli, Ph.D
Chief Executive Officer |
|
Innovation to tackle emerging challenges is our
motto at Julphar. Diabetes, with its alarmingly
increasing incidence, threatens to become a major
disease afflicting sizeable sections of the
population in the Middle East and globally. It was
for this reason that Julphar, a UAE pride in its own
right, decided to enter full- orce the field of bulk
insulin crystals production. In its mission to meet
the exploding demands for diabetes care segment,
Julphar, a regional powerhouse, established a
world-class insulin production facility Julphar XI.
The facility’s production will widen the product
range and boost Julphar’s market presence, already a
major global pharmaceutical company.
|
|
We have a firm commitment to keep up-to-date
with the healthcare needs of the region by offering
highly sophisticated solutions and technologies to a
wide range of healthcare burdens, including
diabetes. With the establishment of our facilities,
we are well poised to enter new therapeutic segments
offering more complex and innovative products. Our
look into the future has a strong emphasis on
biotechnology. While we leverage technology to move
into new therapeutic products to address serious
healthcare threats, we are also eyeing expansion to
continue providing solutions to our discerning
global consumer.
|
Top